Skip to main content
SpringerLink
Log in

In Vivo Methods for Screening and Preclinical Testing

Use of Rodent Solid Tumors for Drug Discovery

  • Chapter
Anticancer Drug Development Guide

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

The classic question in the field of drug discovery is: Which tumor model is a satis-factory predictor for cancer in humans? The classic answer is: None of them!

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Corbett T, Valeriote F, Baker L. Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs 1987; 5: 3–20.

    Article  PubMed  CAS  Google Scholar 

  2. Corbett TH, Valeriote FA. Rodent models in experimental chemotherapy, In: Kallman RF, ed. The Use of Rodent Tumors in Experimental Cancer Therapy: Conclusions and Recommendations. Pergamon. 1987: 233–247.

    Google Scholar 

  3. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 1977; 40: 2660–2680.

    Article  PubMed  CAS  Google Scholar 

  4. Corbett TH, Griswold DP, Roberts BJ, Peckham JC, Schabel FM Jr. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treatment Rep 1978; 62 (10): 1471–1488.

    CAS  Google Scholar 

  5. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, Schabel FM Jr. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984; 44: 717–726.

    PubMed  CAS  Google Scholar 

  6. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy asays, with a note on carcinogen structure. Cancer Res 1975; 35: 2434–2439.

    PubMed  CAS  Google Scholar 

  7. Corbett TH, Griswold DP Jr, Roberts BJ, Schabel FM Jr. Cytotoxic adjuvant therapy and the experimental model. In: Stoll BA, ed. New Aspects of Breast Cancer vol. 4. Systemic Therapy in Breast Cancer. London: William Heinemann Medical Books. 1981: 204–243.

    Google Scholar 

  8. Pitot HC, Shires TK, Moyer G, Garret CT. Phenotypic variability as a manifestation of translational control. In: Busch H, ed. The Molecular Biology of Cancer. Londen: Academic. 1974: 524–533.

    Google Scholar 

  9. Hirshberg E. Patterns of response of animal tumors to anticancer agents: a systematic analysis of the literature in experimental cancer chemotherapy—1945–1958. Cancer Res 1963; 23: 521–1084.

    Google Scholar 

  10. Griswold DG, Laster WR Jr, Snow MY, Schabel FM Jr, Skipper HE. Experimental evaluation of potential anticancer agents. XII. Quantitative drug response of the SA180, CA755, and leukemia L1210 systems to a “standard list” of “active” and “inactive” agents. Cancer Res 1963; 23: 271–521.

    Google Scholar 

  11. Skipper HE, Wilcox WS, Schabel FM Jr, Laster WR Jr, Mattil L. Experimental evaluation of potential anticancer agents. X. A specific test for distinguishing false positives. Cancer Chemother Rep 1963; 29: 1–62.

    PubMed  CAS  Google Scholar 

  12. Heston WE. Genetics: Animal Tumors. In: Becker FF, ed. Cancer, A Comprehensive Treatise, vol. 1. New York: Plenum. 1975: 33–57.

    Chapter  Google Scholar 

  13. Pott P. Cancer of the scrotum. In: Chirurgical Observations. London: Hawkes, Clarke, and Collons. 1775: 63–68.

    Google Scholar 

  14. Hanau A. Erfolgreiche experimentelle Übertragung von karzinom. Fortschr d Med. 1889; 9: 5–12.

    Google Scholar 

  15. Staats J. Standardized nomenclature for inbred strains of mice: eighth listing. Cancer Res 1985; 45: 945–977.

    PubMed  CAS  Google Scholar 

  16. Yamagawa K, Ichikawa K. Experimentelle Studie über die Pathogenese der epithelialgeschwulste. Mitteilungen Med Facultat Kaiserl Univ Tokyo 1915; 15: 295–344.

    Google Scholar 

  17. Kennaway E. The identification of a carcinogenic compound in coaltar. Br Med J 1975; 2: 749–752.

    Article  Google Scholar 

  18. Zubrod CG. Historic milestones in curative chemotherapy. Semin Oncol 1979; 6: 490–505.

    PubMed  CAS  Google Scholar 

  19. Goldin A, Schepartz SA, Venditti JM, DeVita VT. Historical development and current strategy of the National Cancer Institute drug development program, Chapter V. Methods in Cancer Res. 1979; 16: 165–245.

    Google Scholar 

  20. Schabel FM Jr. Laboratory methods for the detection and development of clinically useful anticancer drugs. In: Burchenal JH, Oettgen HF, eds. Cancer: Achievements, Challenges, and Prospects for the 1980’s, vol. 2. New York: Grune & Stratton. 1981: pp. 9–26.

    Google Scholar 

  21. Venditti JM. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary. Cancer Treatment Rep 1983; 67: 767–772.

    CAS  Google Scholar 

  22. Venditti JM, Wesley RA, Plowman J. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. In: Garattini S, Coldin A, Hawking F, eds. Advances in Pharmacology and Chemotherapy, vol. 20. Orlando, FL: Academic. 1984: 1–20.

    Google Scholar 

  23. Zee-Cheng RKY, Cheng CC. Screening and evaluation of anticancer agents. Methods and Findings Exp Clin Pharmacol 1988; 10: 67–101.

    CAS  Google Scholar 

  24. Boyd MR. Status of the NCI preclinical antitumor drug discovery screen. Principles and Prac Oncol 1989; 3: 1 - 12.

    Google Scholar 

  25. Boyd MR. The future of new drug development. In: Neiderhuber JE, ed. Current Therapy in Oncology. Philadelphia: B.C. Decker. 1993: 11–22.

    Google Scholar 

  26. Frei E III. The national cancer chemotherapy program. Science 1982; 217: 600–606.

    Article  PubMed  Google Scholar 

  27. Hart IR, Talmadge JE, Fidler IJ. Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth. Cancer Res 1981; 41: 1281–1287.

    PubMed  CAS  Google Scholar 

  28. LoRusso PM, Polin L, Aukerman SL, Redman BG, Valdivieso M, Biernat L, Corbett TH. Antitumor efficacy of Interleukin-2 alone and in combination with Adriamycin and Dacarbazine in murine solid tumor systems. Cancer Res 1990; 50: 5876–5882.

    PubMed  CAS  Google Scholar 

  29. Corbett TH, Valeriote FA, Polin L, et al. Discovery of solid tumor active agents using a soft agar colony formation disk-diffusion assay. In: Valeriote, FA Corbett TH, Baker LH, eds. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and development. Boston/Dordrecht, London: Kluwer Academic Publishers. 1992: 33–87.

    Google Scholar 

  30. Corbett TH, Valeriote F, LoRusso P, Polin L, et al. Tumor models and the discovery and secondary evaluation of solid tumor active agents. Int J Pharmacognosy 1995; 33 Suppl. 102–122.

    Article  CAS  Google Scholar 

  31. Grindey GB. Current status of cancer drug development: failure or limited success? Cancer Cells 1990; 2: 163–171.

    PubMed  CAS  Google Scholar 

  32. Stahelin H, von Wartburg A. The chemical and biological route for Podophyllotoxin Glucoside to Etoposide: Ninth Cain Memorial Award Lecture. Cancer Res 1991; 51: 5–15.

    PubMed  CAS  Google Scholar 

  33. Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold DP Jr, Schabel FM Jr. Toxicity and anticancer activity of a new triazine antifolate (NSC-127755). Cancer Res 1982; 42: 1707–1715.

    PubMed  CAS  Google Scholar 

  34. Corbett TH, Bissery M-C, LoRusso P-M, Polin L. 5-Fluorouracil containing combinations in murine tumor systems. Invest New Drugs 1989; 7: 37–49.

    Article  PubMed  CAS  Google Scholar 

  35. LoRusso PM, Wozniak AJ, Polin L, Capps D, Leopold WR, Werbel LM, Biernat L, Dan ME, Corbett TH. Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res 1990; 50: 4900–4905.

    PubMed  CAS  Google Scholar 

  36. Corbett TH, Roberts BJ, Trader MW, Laster WR Jr, Griswold DP Jr, Schabel FM Jr. Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treatment Rep 1982; 66 (5): 1187–1200.

    CAS  Google Scholar 

  37. Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH. Establishment of cross-resistance profiles for new agents. Cancer Treatment Rep 1983; 67: 905–922.

    Google Scholar 

  38. Schabel FM Jr, Griswold DP Jr, Corbett TH, Laster WR Jr, Mayo JC, Lloyd HH. Testing therapeutic hypotheses in mice and man. Observations on the therapeutic activity against advanced solid tumors of mice treated with anticancer drugs that have demonstrated or potential clinical utility for treatment of advanced solid tumors of man. In: Busch H, DeVita V Jr, eds. Cancer Drug Development. Part B. Methods in Cancer Research, vol. 17. New York: Academic. 1979: 3 - 51.

    Google Scholar 

  39. Corbett T, Lowichik N, Pugh S, et al. Antitumor activity of TV-[[1 -[[2-(diethylamino)ethyl] amino]-9-oxo-9H-Thioxanthen-4-yl]methyl]methanesulfonamide (WIN33377) and analogs. Exp Opinion Invest Drugs 1994; 3: 1281–1292.

    Article  CAS  Google Scholar 

  40. Corbett TH, Roberts BJ, Lawson AJ, Leopold WR III. Curative chemotherapy of advanced and disseminated solid tumors of mice. In: Jacobs JR, Al-Sarraf M, Crissman J, Valeriote F, eds. Scientific and Clinical Perspectives in Head and Neck Cancer Management: Strategies for Cure. New York: Elsevier Scientific Publishing. 1987: 175–192.

    Google Scholar 

  41. Wentland MP, Perni RB, Powles RG, Hlavac AG, Mattes KC, Corbett TH, Coughlin SA, Rake JB. Anti-solid tumor efficacy and preparation of N- [[1 - [[2-(Diethylamino)ethyl]amino] -9-Oxo-9H-Thioxanthen-4-Yl]methyl]methanesulfonamide (Win 33377) and related derivatives. Bioorganic Med Chem Lett 1994; 4 (4): 609–614.

    Article  CAS  Google Scholar 

  42. Horwitz JP, Massova I, Wiese TE, Besler BH, Corbett TH. Comparative molecular field analysis of the tumor activity of 9H-Thioxanthen-9-one derivatives against pancreatic ductal carcinoma 03. J. Med Chem 1994; 37: 781–786.

    Article  PubMed  CAS  Google Scholar 

  43. LoRusso PM, Polin L, Biernat LA, Valeriote FA, Corbett TH. Activity of detallilptinium (NSC 311152) against solid tumors of mice. Invest New Drugs 1990; 8: 253–261.

    Google Scholar 

  44. Bissery M-C, Gurnard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC-628503), a Taxol analog. Cancer Res 1991; 51: 4845–4852.

    PubMed  CAS  Google Scholar 

  45. Annual Progress Report to Division of Cancer Treatment, National Cancer Institute on Primary Screening and Development and Application of Secondary Evaluation Procedures for Study of New Materials with Potential Anticancer Activity. Section 21. Evaluation of Single Agents and Combinations of Chemotherapeutic Agents in Mouse Colon Carcinomas. Southern Research Institute, Contract NOl-CM-43756, March 15, 1982.

    Google Scholar 

Download references

Authors
  1. Thomas Corbett PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fred Valeriote PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patricia LoRusso DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lisa Polin PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chiab Panchapor BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Susan Pugh BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kathryn White BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Juiwanna Knight BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lisa Demchik BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Julie Jones BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lynne Jones BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Loretta Lisow BA
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dana-Farber Cancer Institute, Boston, MA, USA

    Beverly A. Teicher

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Corbett, T. et al. (1997). In Vivo Methods for Screening and Preclinical Testing. In: Teicher, B.A. (eds) Anticancer Drug Development Guide. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4615-8152-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-8152-9_5

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4615-8154-3

  • Online ISBN: 978-1-4615-8152-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation